“The Price of Life” is a powerful and thought-provoking documentary that delves into the complex and often controversial world of healthcare and the rationing of high-cost cancer drugs by the National Institute for Health and Clinical Excellence (NICE). The film, directed by Adam Wishart, offers a unique and unprecedented look at the decision-making process behind which medications are made available to patients in the National Health Service (NHS).
Through interviews with key decision-makers at NICE, patients in desperate need of life-extending treatments, and representatives from the pharmaceutical companies that discovered and profited from these drugs, the film shines a light on the difficult choices that must be made when resources are limited.
The film centers around the case of the cancer drug Revlimid, and the difficult decision that NICE must make about whether or not to offer it to patients on the NHS. The film offers a sobering look at the human cost of these decisions and the impact they can have on patients and their families.
At the same time, the film raises important ethical questions about the role of pharmaceutical companies in the healthcare system and the role of profit in the development and distribution of life-saving drugs.
Overall, “The Price of Life” is a thought-provoking and powerful documentary that offers a unique and important perspective on the complex and often controversial world of healthcare.
